consumers should review OpenLoop's telehealth consent at openloophealth.com/telehealth-consent and ask FeelGood support specific data privacy questions before enrollment FDA compounded GLP-1 adverse events: The FDA received 1,150+ adverse event reports related to compounded semaglutide/tirzepatide as of July 2025, including dosing errors with vial-based injectables
The revised Atlanta classification of acute pancreatitis: its importance for the radiologist and its effect on treatment
You deserve a clear plan, not a confusing denial letter and no next step
Addressing Metabolic Dysfunction as an Independent Cancer Risk Factor Accumulating evidence positions metabolic dysfunction characterised by insulin resistance, hepatic steatosis, dyslipidaemia, and visceral adiposity as a more powerful and proximate predictor of cancer risk than elevated body weight alone
They are, however, the most effective obesity pharmacotherapy weve ever had
Clinical Evidence and Real-World Outcomes in Women While large-scale trials of GLP-1 medications have included women across menopause stages, dedicated research on semaglutide specifically for menopausal weight gain remains limited